European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Nov 23, 2015
During the last decade neoadjuvant endocrine therapy (NET) has moved from being reserved for elderly and frail non-chemotherapy candidates to a primary systemic modality in selected patients with hormone sensitive breast cancer. Neoadjuvant hormonal ...
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
Nov 15, 2025
Breast cancer is one of the most common tumors in women, and early screening can significantly reduce mortality rates. Meanwhile, accurately identifying HER2-positive and HER2-negative subtypes of breast cancer is critical for helping doctors determi...
UNLABELLED: The standard approach of using one-size-fits-all endocrine therapy for hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancers has faced significant challenges because of variations in tr...
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
Sep 1, 2025
PURPOSE: With increasing use of human epithelial growth factor receptor two (HER2)-targeted therapies, outcomes for numerous breast cancer patients have improved. Nevertheless, patients with HER2-positive tumours face a comparatively heightened risk ...
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
Sep 1, 2025
BACKGROUND: The TCbHP regimen, consisting of combining docetaxel (T), carboplatin (Cb), trastuzumab (H), and pertuzumab (P), is the preferred neoadjuvant treatment for locally advanced human epidermal growth factor 2 (HER2)-positive breast cancer. Ho...
PURPOSE: Gene expression profiles are used for decision making in the adjuvant setting in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. While algorithms to optimize testing exist for RS/Oncotype Dx, no such efforts have focused ...
Archives of pathology & laboratory medicine
Aug 1, 2025
CONTEXT.—: Precise determination of biomarker status is necessary for clinical trial enrollment and endpoint analyses, as well as for optimal treatment determination in real-world practice. However, variabilities may be introduced into this process d...
Breast cancer is a significant global health concern, where precise identification of proteins like Human Epidermal Growth Factor Receptor 2 (HER2) in cancer cells via Immunohistochemistry (IHC) is pivotal for treatment decisions. HER2 overexpression...
Our study investigated the predictive efficacy of AI-based Machine Learning (ML) model for determining HER2 status in a population of 3424 breast cancer patients. Multivariate logistic regression analysis identified several independent variables that...
Cancer imaging : the official publication of the International Cancer Imaging Society
May 12, 2025
PURPOSE: According to the updated classification system, human epidermal growth factor receptor 2 (HER2) expression statuses are divided into the following three groups: HER2-over-expression, HER2-low-expression, and HER2-zero-expression. HER2-negati...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.